new microsoft office power point presentation
TRANSCRIPT
![Page 1: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/1.jpg)
PROF.DR.P.VASANTHII’S UNITDR.V.GIRIDHARAN
A CASE OF HYPONATREMIA
![Page 2: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/2.jpg)
• 68 yr old lady known diabetic and hypertensive for the past 2 years presented to zerodelay with h/o
• chest pain,breathlessness -3 hrs duration• No h/o palpitation• No h/o sweating• No h/o decreased urine output• No h/o cough or expectoration• No h/o fever• No h/o head ache• No h/o myalgia
![Page 3: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/3.jpg)
• No h/o abdomen pain• No h/o loose stools• No h/o vomiting• No h/o weakness of limbs• No h/o any visual distrubances• No h/o seizure • No h/o syncope• No h/o dizziness• No h/o bladder /bowel distrubances• No h/o loss of conciousness• No h/o altered behaviour
![Page 4: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/4.jpg)
ON EXAMINATION• Pt concious,oriented• Anxious• Dyspnoeic/tachypnoeic (28/min)• Afebrile• No pallor• Not cyanosed• No clubbing• No icterus• No pedal edema• Jvp not elevated• No lymphadenopathy
![Page 5: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/5.jpg)
• S1 s2 –present,no murmur• RS-nvbs present, no crepitations• P/A- soft, no tenderness no organomegally bowel sounds +• CNS-nfnd
![Page 6: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/6.jpg)
• Known diabetic,hypertensive for past two years–chest pain for 4 hrs ,
• Vitals stable,• ECG-ST elevation 1,Avl,v2-v4,• Echo-hypokinesia distal 2/3 of ivs, aw,apex.• EF-45./.• Thrombolysed with streptokinase.• In ICCU with cardiac drugs
![Page 7: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/7.jpg)
• No other positive history .• Prior h/o right hemiparesis 2 yrs ago but recovered• Pt was concious ,well oriented at admission and
after lysis.• Pt was dyspnoeic ,tachypnoeic (rate 28/min)• Not febrile• No pallor• Not cyanosed,no clubbing,no icterus• Jvp –not elevated
![Page 8: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/8.jpg)
DAY 1
• S1 s2 +,no murmur.• S3,s4 not heared.• Rs-nvbs ,no crepitations• P/A-soft• CNS-NFND
![Page 9: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/9.jpg)
DAY 1
• BP-156/90• Pulse-106/min• SPO2-96./. With 4 lit/min o2 (mask)• ECG- ST elevation lead 1,aVL ,v2-v4
![Page 10: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/10.jpg)
DAY 1
BLOOD SUGAR 268 mg/dl
UREA 26 mg/dl
S.CREATININE 0.8 mg/dl
Na+ 139 mg/dl
K+ 3.9 mg/dl
CPK MB 32 UNITS/L
URINE KETONES NEGATIVE
![Page 11: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/11.jpg)
DAY 1PARAMETER RESULT
HB ./. 10.2 g/dl
TOTAL COUNT 8,600
DIFFERENTIAL COUNT 65/30/5
ESR 8/16
PLATELET COUNT 2.4 lakhs
RBC 3 million
PCV 30
![Page 12: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/12.jpg)
DAY 1
• Pt was thrombolysed with streptokinase• Pt doing well till that afternoon• After 5 pm on that day pt developed altered
sensorium• Neurological examination shows paucity of
movement on right side • Pt was drowsy,disoriented• Suspected ICH ( complication of lysis)
![Page 13: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/13.jpg)
DAY 1
• Emergency CT taken –didn,t show any haemorrhage
• Infarct seen in left cerebellar hemesphire• MRI was planned next day• Neuro opinion was obtained• Advised MRI/electrolytes• Mean while pt was on cardiac drugs
![Page 14: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/14.jpg)
DAY 1
BLOOD SUGAR 256 mg/dl
UREA 31 mg/dl
S.CREATININE 1.1 mg/dl
Na+ 107 mg/dl
K+ 4.2 mg/dl
![Page 15: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/15.jpg)
• Pt was treated cautiously with iv fluid normal saline 50-75 ml/hr ,while monitoring signs for volume overload and urine output
![Page 16: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/16.jpg)
DAY 2TIMING Na+ LEVELS
MORNING LOW RANGE
AN 111 meq/l
EVENING 108 meq/l
MRI BRAIN ACUTE LEFT CEREBELLAR INFARCT CHRONIC INFARCT LEFT TEMPARO-PARIETAL REGION
![Page 17: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/17.jpg)
1 •SHT /T2DM
2 •ACS/AWMI
3 •CVA/CEREBELLAR INFARCT
![Page 18: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/18.jpg)
SHT/T2DM
ACS/AWMI
CVA/ACUTE CEREBELLAR INFARCT
HYPONATREMIA
?
![Page 19: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/19.jpg)
What next?
• In the back ground of
SHT DM2 OLD CVA ACS/AWMI ACUTE LT CEREBELLAR
INFARCT HYPONATREMIA
![Page 20: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/20.jpg)
• Hypo or hypernatremia is primarily is a disorder of water balance
![Page 21: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/21.jpg)
hyponatremia
• Na+ <135 meq/l• Subdivided diagnostically into three
groups,depending upon clinical history and volume status.
hyponatremia
hypovolemic
euvolemic
hypervolemic
![Page 22: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/22.jpg)
![Page 23: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/23.jpg)
![Page 24: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/24.jpg)
Hyponatremia is classified according to volume status, as follows
• Hypovolemic hyponatremia: decrease in total body water with greater decrease in total body sodium
• Euvolemic hyponatremia: normal body sodium with increase in total body water
• Hypervolemic hyponatremia: increase in total body sodium with greater increase in total body water
![Page 25: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/25.jpg)
![Page 26: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/26.jpg)
IN OUR PATIENT
HYPONATREMIA
1)ACS2)AWMI
3)MILD PEDAL EDEMA4)NO JVP
1)SHT2)T2DM/HYPERGLYCEMIA
3)CREATININE-1.2/INTERSTITIAL NEPHRITIS
1)OLD CVA2)RECURRENT CVA
3)ACUTE CEREBELLAR INFARCT
HYPERVOLEMIA? HYPOVOLEMIC? EUVOLEMIC/HYPOVOLEMIC?
![Page 27: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/27.jpg)
PSEUDO HYPONATREMIA
• Hyperlipidemia • Hyperproteinemia• Hypertonic (or translocational) hyponatremia
occurs when osmotically active solutes (glucose or mannitol) draw water from cells.
• For each increase of 100 mg /dl of glucose, sodium declines by 1.6 to 2.4 meq/l
![Page 28: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/28.jpg)
CONFUSED OF HYPO OR EUVOLEMIC?
• When diagnostic uncertainty remains, volume contraction of the extracellular fluid can be ruled out by infusing 2 liters of 0.9% saline over a period of 24 to 48 hours.
• Even though 0.9% saline is not the preferred treatment for SIAD, it is usually safe when the baseline urinary osmolality < 500 mOsm /kg
• correction of the hyponatremia suggests underly ing volume depletion of extracellular fluid.
![Page 29: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/29.jpg)
SERUM OSMOLALITY 267 mOsm/kg
URINE OSMOLALITY 281 mOsm/kg
URINE SODIUM 95 meq/l
Urine chloride 83 mOsm/l
Urine spot k+ 7 meq/l
![Page 30: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/30.jpg)
Thyroid function test
T4 2
TSH 4
7 AM CORTISOL
X RAY CHEST NORMAL
USG ABDOMEN NORMAL KIDNEY SIZE ,1.1 mm left renal calculi,resr normal
![Page 31: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/31.jpg)
S.URIC ACID 4 mg/dl
![Page 32: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/32.jpg)
ADH
• Synthesized in hypothalamus• Transported down to posterior pituitary• Released in response to hyperosmolality (major stimuli,
mediated through osmoreceptors in hypothalamus) or hypovolemia (via baroreceptors in left atrium, aortic arch, etc)
![Page 33: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/33.jpg)
ADH
• Binds to V2 receptors in collecting tubules– stimulates cyclic adenosine monophosphate– leads to insertion of aquaporin-2 channels into apical
membranes
• The goal is to facilitate the transport of solute-free water
![Page 34: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/34.jpg)
SIADH => SIAD• A slight misnomer• The name implies inappropriate secretion• 1/3rd of pts do secrete AVP independent of plasma osmolality• Others exhibit reset osmostat – AVP is fully supressed, but
serum Na level is lower than nl• AVP levels may be undetectable in some pts• Some aquaporin mutations lead to concentrated urine in the
absence of AVP• Therefore, the new term, Syndrome of Inappropriate
Antidiuresis (SIAD) has been proposed
![Page 35: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/35.jpg)
Patterns of plasma levels of arginine vasopressin (AVP; also known as the antidiuretic hormone), as compared with plasma sodium levels in patients with SIAD, are shown. Type A is characterized by unregulated secretion of AVP, type B by elevated basal secretion of AVP despite normal regulation by osmolality, type C by a "reset osmostat," and type
D by undetectable AVP. The shaded area represents normal values of plasma AVP. Adapted from Robertson
![Page 36: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/36.jpg)
DOES AVP NEEDS MEASUREMENT?
• Measurement of the serum level of arginine vasopressin is not recommended routinely, because urinary osmolality above 100 mOsm per kilogram of water is usually sufficient to indicate excess of circulat- ing arginine vasopressin.
![Page 37: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/37.jpg)
![Page 38: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/38.jpg)
Neurological adaptation
• The severity of neurologic symptoms correlates well with the rate and degree of the drop in serum sodium. A gradual drop in serum sodium, even to very low levels, may be tolerated well if it occurs over several days or weeks, because of neuronal adaptation.
![Page 39: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/39.jpg)
SIADH
Hypothalamus receives feedback from:
• Osmoreceptors• Aortic arch baroreceptors• Carotid baroreceptors• Atrial stretch receptors
Any increase in osmolality or decrease in blood volume will stimulate ADH secretion from posterior pituitary.
![Page 40: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/40.jpg)
SIADH - pathophysiologyADH-induced water retentionDilutional hyponatremiaVolume expansion -> secondary natriuresis
Sodium and water lossPotassium loss
Result: Euvolemic hyponatremiaReduced serum osmolalityIncreased urine osmolalityIncreased urine sodium
![Page 41: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/41.jpg)
SIADH - treatment
Treat the underlying cause, if knownFluid Restriction – commonly 800-1000mL/dCorrect Na+ deficit – no more than 10mEq/L
in 24 hours, 18mEq/L in 48 hours0.9% NaCl3% NaClNaCl enteral tablets – 2-3g TIDAdd a loop diuretic
![Page 42: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/42.jpg)
![Page 43: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/43.jpg)
Malignant Diseases
Pulmonary Disorders
Disorders of CNS Drugs Other Causes
CarcinomaLungSmall cellMesotheliomaOropharynxGastrointestinal tractStomachDuodenumPancreasGenitourinary tractUreterBladderProstateEndometriumEndocrine thymomaLymphomasSarcomasEwing's sarcoma
InfectionsBacterial pneumoniaViral pneumoniaPulmonary abscessTuberculosisAspergillosisAsthmaCystic fibrosisRespiratory failure associated with positive-pressure breathing
InfectionEncephalitisMeningitisBrain abscessRocky Mountain spotted feverAIDSBleeding and massesSubdural hematomaSubarachnoid hemorrhageCerebrovascular accidentBrain tumorsHead traumaHydrocephalusCavernous sinusthrombosisOtherMultiple sclerosisGuillain-Barré syndromeShy-Drager syndromeDelerium tremensAcute intermittent polyphyria
Drugs that stimulate release of AVP or enhance its actionChlorpropamideSSRIsTricyclic antidepressantsClofibrateCarbamazepineVincristineNicotineNarcoticsAntipsychotic drugsIfosfamideCyclophosphamideNonsteroidal anti-inflammatory drugsMDMA (ecstasy)AVP analoguesDesmopressinOxytocinVasopressin
Hereditary (gain-of-function mutations in the vasopressin V2 receptor)IdiopathicTransientEndurance exerciseGeneral anesthesiaNauseaPainStress
![Page 44: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/44.jpg)
• SIAD may be difficult to distinguish from cerebral salt wasting, a syndrome of hyponatremia and ex- tracellular-fluid volume depletion in patients with insults to the central nervous system.43,44 The pri- mary feature that differentiates cerebral salt wast- ing from SIAD is extracellular-fluid volume deple- tion, but clinical assessment of volume status is imprecise
![Page 45: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/45.jpg)
![Page 46: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/46.jpg)
![Page 47: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/47.jpg)
![Page 48: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/48.jpg)
Cerebral Salt Wasting
Hyponatremia caused by impaired renal tubular function -> inability of kidneys to conserve salt
Salt wasting leads to volume depletionTwo theories:
Impaired sympathetic neural input -> failure of aldosterone release -> no sodium resorption
BNP release decreases sodium resorption, inhibits renin/aldosterone release, decreases autonomic outflow at level of brainstem
![Page 49: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/49.jpg)
Cerebral Salt Wasting
Commonly occurs in subarachnoid hemorrhage population (7%)
Carcinomatous, infectious meningitisEncephalitisPoliomyelitisCNS tumorsCNS surgery – usually within the first 10 days
![Page 50: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/50.jpg)
CSW
![Page 51: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/51.jpg)
![Page 52: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/52.jpg)
Cerebral Salt Wasting
• Treat with volume repletion– 0.9% NaCl– 3% NaCl is sometimes warranted– Fludrocortisone
![Page 53: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/53.jpg)
MANAGEMENT OF HYPONATREMIAWater deficit
1. Estimate total-body water (TBW): 50% of body weight in women and 60% in men2. Calculate free-water deficit: {([Na+]-140)/140} x TBW3. Administer deficit over 48–72 h, without increasing the plasma Na+ concentration by >10 mM/24 hOngoing water losses
4. Calculate electrolyte-free water clearance, CeH2O:where V is urinary volume, UNa is urinary [Na+], UK is urinary [K+], and PNa is plasma [Na+]Insensible losses
5. 10 mL/kg per day: less if ventilated, more if febrile
Total
6. Add components to determine water deficit and ongoing water loss; correct the water deficit over 48–72 h and replace daily water loss. Avoid correction of plasma [Na+] by >10 mM/d
![Page 54: New microsoft office power point presentation](https://reader036.vdocuments.mx/reader036/viewer/2022070516/58727e691a28abc7068b5c3b/html5/thumbnails/54.jpg)
Remember....• Elevated BUN and creatinine in routine chemistries also can indicate renal dysfunction
as a potential cause of hyponatremia,• whereas hyperkalemia may suggest adrenal insufficiency or hypoaldosteronism.• Serum glucose also should be measured; plasma Na+ concentration falls by 1.6 to 2.4
mM for every 100-mg/dL increase in glucose due to glucose-induced water efflux from cells; this "true" hyponatremia resolves after correction of hyperglycemia.
• Measurement of serum uric acid also should be performed; whereas patients with SIAD-type physiology typically will be hypouricemic (serum uric acid <4 mg/dL),
• volume-depleted patients often will be hyperuricemic.• In the appropriate clinical setting, thyroid, adrenal, and pituitary function should also
be tested;• hypothyroidism and secondary adrenal failure due to pituitary insufficiency are
important causes of euvolemic hyponatremia, • whereas primary adrenal failure causes hypovolemic hyponatremia• A cosyntropin stimulation test is necessary to assess for primary adrenal insufficiency.